Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of 22.1%, reaching US$8.85 billion in 2025 and an impressive US$24.00 billion by ...

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming ...

Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

Days after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs.

Biohaven Ltd. has a one year low of $15.79 and a one year high of $55.70. The company’s fifty day moving average price is $28.43 and its 200 day moving average price is $38.46.

BofA cuts Pfizer’s Q1 2025 EPS estimate by 4.9% and revenue by 2.1% due to updated assumptions. Pfizer stock trades at 7x expected 2024 earnings, lower than peer average; dividend yield stands ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q1 2025 earnings on April 29.

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors ...